Workflow
Sintx Technologies(SINT) - 2024 Q3 - Quarterly Report
SINTSintx Technologies(SINT)2024-11-12 20:50

Revenue Performance - For the three months ended September 30, 2024, total product revenue increased by 0.2million,or1180.2 million, or 118%, compared to the same period in 2023[108]. - For the nine months ended September 30, 2024, total product revenue increased by 0.4 million, or 64%, compared to the same period in 2023[109]. - Grant and contract revenue decreased by 0.1million,or150.1 million, or 15%, for the three months ended September 30, 2024, compared to the same period in 2023[108]. Profit and Loss - Gross profit for the three months ended September 30, 2024, increased by 0.3 million, or 5%, compared to the same period in 2023[106]. - Net loss for the three months ended September 30, 2024, was 6.2million,comparedtoanetlossof6.2 million, compared to a net loss of 3.2 million for the same period in 2023, representing a 96% increase in loss[107]. - For the nine months ended September 30, 2024, the company incurred a net loss of 9.3million,comparedtoanetlossof9.3 million, compared to a net loss of 5.9 million for the same period in 2023, reflecting an increase in losses of approximately 57.6%[121]. Expenses - Research and development expenses decreased by 1.7million,or681.7 million, or 68%, for the three months ended September 30, 2024, compared to the same period in 2023[112]. - General and administrative expenses decreased by 0.2 million, or 19%, for the three months ended September 30, 2024, compared to the same period in 2023[113]. - Sales and marketing expenses decreased by 0.2million,or660.2 million, or 66%, for the three months ended September 30, 2024, compared to the same period in 2023[115]. - Total operating expenses increased by 2.8 million, or 68%, for the three months ended September 30, 2024, compared to the same period in 2023[107]. - Armor exit costs increased by 4.5million,or1004.5 million, or 100%, for the three months ended September 30, 2024, compared to the same period in 2023[116]. Cash Flow - Cash used in operating activities decreased to 7.5 million for the nine months ended September 30, 2024, from 11.0millioninthesameperiodof2023,areductionof11.0 million in the same period of 2023, a reduction of 3.5 million or 31.8%[140]. - Other income decreased by 1.7million,or361.7 million, or 36%, for the nine months ended September 30, 2024, primarily due to a decrease in the fair value of derivative liabilities[120]. Capital and Financing - The company raised approximately 12.0 million from a public offering on February 10, 2023, and 4.0millionfromanotherpublicofferingonFebruary2,2024[123][124].Thecompanyhasanaccumulateddeficitof4.0 million from another public offering on February 2, 2024[123][124]. - The company has an accumulated deficit of 280.0 million as of September 30, 2024, compared to 270.7millionasofDecember31,2023[121].Theworkforcewasreducedfrom40to23employees,resultinginexpensesofapproximately270.7 million as of December 31, 2023[121]. - The workforce was reduced from 40 to 23 employees, resulting in expenses of approximately 407,000 during the three months ended September 30, 2024[135]. - TA&T entered into a Business Loan of approximately 350,000ataninterestrateof3.75350,000 at an interest rate of 3.75% per annum, which was paid in full during Q1 2023[143]. - Personal Loans totaling approximately 350,000 were repaid in full during Q3 2024, with payments structured in 24 equal monthly installments[144]. - As of September 30, 2024, the Wells Fargo line of credit had no outstanding balance and the account was closed[145]. - A Premium Finance Arrangement for Director and Officer insurance was established, financing approximately 239,000,withanoutstandingbalanceof239,000, with an outstanding balance of 70,000 as of September 30, 2024[145]. - Another Premium Finance Arrangement for commercial liability insurance financed approximately 117,000,withanoutstandingbalanceof117,000, with an outstanding balance of 64,000 as of September 30, 2024[146]. Strategic Outlook - The company anticipates requiring substantial future capital to continue operations and fund research and development activities[121]. - The company is exploring strategic transactions, including acquisitions and partnerships, to enhance its business focus[130]. - The company is evaluating a shift towards advancements in the medical device sector, leveraging expertise in advanced ceramics and biomaterials[131]. Accounting and Compliance - There are no off-balance sheet arrangements as defined in Item 303(a)(4) of Regulation S-K[147]. - Significant accounting policies and estimates have not materially changed for the nine months ended September 30, 2024[148]. - The company is currently evaluating new accounting pronouncements as discussed in Note 1 of the Quarterly Report[149].